HPV-16 variant analysis of E6, E7, L1 genes and long control region in cervical cancer patients from North India by Pande, Shailja et al.
 1 
HPV-16 Variant Analysis of E6, E7, L1 Genes and Long Control 
Region in Cervical Cancer Patients from North India 
 
Shailja Pande1, Neeraj Jain1, Bhupesh K Prusty1, Suresh Bhambhani2, Sanjay Gupta2, Rajyashri       
Sharma3, Swaraj Batra4, Bhudev C. Das1*  
 
1Division of Molecular Oncology, 2 Division of Cytopathology, Institute of Cytology and Preventive 
Oncology (ICMR), I-7, Sector 39, Noida 201301, INDIA 
3Department of Obsteritics and Gynecology, JNMCH, Aligarh 
4Department of Obsteritics and Gynecology, LNJP, New Delhi 
 
Running Title: HPV 16 variants in cervical cancer from India. 
 
Key Words:   HPV 16, Prototype, Variants, Sequence, Cervix cancer. 
 
 
 
*Corresponding Author: Bhudev C. Das, Ph.D., Division of Molecular Oncology, Institute of 
Cytology and Preventive Oncology, I-7, Sector 39, Noida 201301 INDIA Tel.: 91-120-2578837;  
Fax: 91-120-2579473.  
E-mail: bcdas48@hotmail.com 
                                              
 
ACC
EPT
ED
 Copyright © 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
J. Clin. Microbiol. doi:10.1128/JCM.02202-07 
JCM Accepts, published online ahead of print on 16 January 2008
 2 
                                                             ABSTRACT 
                       
 High risk human papillomaviruses particularly, HPV types 16 and 18 play a cardinal 
role in the aetiology of cervical cancer. The most prevalent HPV type 16 shows intratypic 
sequence variants which are known to differ in oncogenic potential and geographic distribution. 
This study is designed to analyze sequence variations in E6, E7, L1 and LCR regions of HPV 16 
in cervical cancer patients to identify most prevalent and novel HPV 16 variants and to correlate 
them with the severity of the disease. Cervical biopsies from sixty HPV16 positive cancer cases 
were analyzed by PCR and DNA sequencing. The most frequently observed variations were 
T350G (100%) in E6, T789C (87.5%) in E7, A6695C (54.5%) in L1 and G7521A (91.1%) in 
LCR. In addition, only one novel variant (T527A) in E6 and four new variants each in L1 
(A6667C, A6691G, C6906T, A6924C) and in LCR (C13T, A7636C, C7678T, G7799A) were 
identified. While E7 was found to be highly conserved, the variant 350G of E6 was most 
prevalent in all the histopathological grades. Majority of LCR variants were found at the YY1 
transcription factor binding sites. Interestingly, a complete absence of Asian Lineage and a high 
prevalence of European lineages in E6, E7, L1 and LCR (85%, 86.7%, 67.7% and 63.3% 
respectively) indicate possible epidemiological linkage between Europe and India with regard to 
the dissemination of HPV 16 infections in India.  
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HPV-16 Variant Analysis of E6, E7, L1 Genes and Long Control 
Region in Cervical Cancer Patients from North India 
 
Cervical cancer is the major cancer in Indian women and a leading cause of cancer deaths. 
Every year more than 1, 30,000 new cases and about 70,000 deaths are recorded. Persistent infection of 
specific types of high risk human papillomaviruses (HR-HPVs) is essential for progression of cervical 
lesions(6, 11, 31, 60) and it is this subset of women that are likely to develop cancer subsequently (3, 
4, 27, 40).Various studies have demonstrated that more than 70% of invasive cervical cancers harbor 
HPV16 and HPV18 (17, 31) and  the products of viral transforming E6 and E7 genes are shown to 
contribute to tumorigenesis by functionally inactivating two important cellular tumor suppressor 
proteins, the p53 and the Rb, respectively (5, 14, 30, 55).
 
More than 100 types of HPV are known but only about 30 types are associated with anogenital 
cancer. According to Papillomavirus Nomenclature Committee, a new HPV type is defined by 
nucleotide sequence variation of more than 10% compared with other known HPV types in the E6, E7 
and L1 open reading frames (ORFs). Those differing by 2-10% variations are referred to as subtypes 
whereas intratype variants may vary up to 2% in the coding region and 5% in the non-coding region 
when compared to that of prototype (2, 10).  
On the basis of sequence variations in E6, L1, L2 and LCR  HPV 16 variants have been 
identified and grouped into six distinct phylogenetic branches, such as E (European), AA (Asian-
American), Af1 (African 1), Af2 (African 2), As (Asian), and NA (North American) (54, 56, 57). 
These variants have been found to show different geographic distribution with a varied oncogenic 
potential. A number of sequence variations have been reported in HPV 16 E6, E7, L1 gene as well as 
in LCR in cervical cancer (33, 39, 48, 55, 56). Studies have also shown that specific intratype variants 
may influence persistence of HPV infection and progression of precursor lesions to cancer (27, 58, 59). 
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HPV variants may also affect virus assembly, immunologic response, pathogenecity, p53 degradation, 
immortalization activity and regulation of transcription (15,18, 24, 25, 37, 51). An immediate impact 
of these variations will be on the sensitivity and specificity of different PCR based genotype diagnostic 
methods.  
  Of two HPV-16 oncogenes E6 and E7; the E6 has been found to show more variations 
compared to E7 which is relatively conserved (48, 50, 56, 58, 59). The analysis of the L1 gene that 
codes for the viral major capsid protein is of immense importance because of its high diagnostic value. 
The range of intratype variation observed in this region allows the distinction and assessment of known 
and novel HPV types (46). This is also an important target for the development of HPV vaccines. Very 
few reports are available on HPV variants from this region (9, 56). The long control region (LCR), 
which regulates viral transcription, has been found to be the most variable region of the HPV-16 
genome (41, 53, 56). Several authors have evaluated association of specific HPV 16 variants with viral 
persistence and the development of CIN lesions (3, 27, 34, 50, 52).  
 In India, as high as 98% of the cervical carcinoma cases are found to harbor HPV infection and 
the most prevalent (~80%) type is HPV-16 ( 7, 8, 22). Although the prevalence of HPV and cervical 
cancer in India is highest in the world, there is not much data on HPV variants from different regions 
of the Indian subcontinent. In the present study we have examined the sequence variation in E6, E7, L1 
and long control region (LCR) of the most prevalent high risk HPV type 16 and correlated them with 
the age of women, histopathologic grades of tumor and oncogenic potential.  
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MATERIALS AND METHODS 
Study population and specimen collection. Out of a total of 90 tumor samples screened by 
standard procedure (20, 38), sixty HPV-16 positive cervical cancer cases were recruited for the variant 
analysis in the present study. The tumor samples were part of biopsies collected for routine diagnosis 
of cervical cancer from the Cancer Clinic of the Department of Gynecology and Obstetrics, Lok Nayak 
Hospital, New Delhi and Jawaharlal Nehru Medical College, Aligarh. Fresh tumor biopsies were 
collected in chilled phosphate buffered saline (PBS) and stored at -70°C deep freezer for further 
processing later. Informed consent was obtained from all the patients and the study was ethically 
approved by the Institutional Ethical Committee. Diagnosis of histopathological grades was done by 
two Pathologists independently. In the case of discrepancies, it was reconfirmed by the third 
Pathologist to arrive at a final decision. 
DNA extraction and typing of HPV. High molecular weight genomic DNA from cervical 
biopsies was isolated by the standard method of proteinase K digestion and phenol chloroform 
extraction routinely followed in our laboratory (8, 20). 
      Detection of HPV and typing of high-risk HPV types 16 and 18 was carried out using consensus 
and type-specific primers described earlier (20, 38). Amplification of β-globin gene served as the 
internal control. PCR was performed using the in-house PCR-protocol routinely followed in our 
laboratory (7, 8, 17). Briefly, the method involved a 25µl reaction mix containing 100-200ng DNA, 
10mM Tris-Cl (pH 8.4), 50mM KCl, 1.5mM MgCl2, 12.5µM of each dNTPs (dATP, dCTP, dGTP and 
dTTP), 5 pmoles of each oligonucleotide primer and 0.5U Taq DNA Polymerase (Applied Biosystems, 
US). The temperature profile used for amplification constituted an initial denaturation at 95°C for 5min 
followed by 30 cycles with denaturation at 95°C for 30sec, annealing at 55°C for 30sec and extension 
at 72°C for 30sec which was extended for 4min in the final cycle. The oligonucleotide primers were 
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synthesized in an automated Applied Biosystems DNA Synthesizer (Model 381A, Applied Biosystems 
Inc., Foster City, CA, USA) and HPLC purified. 
Variant analysis of E6, E7, L1 gene and LCR of HPV type 16 by PCR and direct 
sequencing. HPV 16 E6, E7 and LCR specific PCR was performed with specific primers for HPV 16 
E6 flanking the region (nt 83-559) with amplicon size 476 bp: 5’-GAA ACC GGT TAG TAT AAA 
AGC AGA C-3’ and 5’-AGC TGG GTT TCT CTA CGT GTT CT-3’; for E7 (nt 562-858) with 
amplicon size 296 bp: 5’-CCA TAA TAT AAG GGG TCG GTG GA-3’ and 5’-TTT TTC CAC TAA 
CAG CCT CTA CAT-3’; for LCR (nt 7437-7456, 119-147) amplicon size 617 bp: 5’-CCA TTT TGT 
AGC TTC AAC CCG-3’ and 5’-AAG TGT GGT AAC TTT CTG GGT CGC TCC TG-3’(54). L1 
gene was amplified partially (450 bp) using MY 11/MY 09 consensus primer sequences: 5’-GCM 
CAG GGW CAT AAY AAT GG-3’ and 5’-CGT CCM ARR GGA WAC TGA-3’ where M=A+C, 
W=A+T, Y=C+T and R=A+G (38). 
  For variant analysis, the PCR products were directly sequenced on an automated DNA 
sequencer (310 ABI Prism Genetic Analyzer, Applied Biosystems, USA) according to the 
manufacturer’s protocol. PCR products were first purified using ammonium acetate/ ethanol 
precipitation method to remove unused dNTPs and primers, and then cycle sequenced using the BIG 
Dye Terminator Sequencing Ready Reaction Mix (Applied Biosystems, USA) on Gene Amp PCR 
9700 (Applied Biosystems, USA). The raw data was collected using ABI Prism 310 collection 
software, analyzed using sequencing analysis software V3.4.1 on a MAC operating system V9.1 and 
compared with the sequence Gen Bank/EMBL/DDBJ U89348. All the samples were reverse 
sequenced to corroborate the findings. 
Identification of variants. Variants were identified using the prototype sequence (HPV 16R), 
which belongs to the European lineages, as standard for comparisons and nucleotide position 
numbering (32) and variants were classified in six major branches as European (E), Asian-American 
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(AA), Asian (As), African1 (Af1), African 2 (Af2) and North American (NA) as described by Yamada 
et al. (56). 
Statistical analysis. Statistical analysis was performed using the χ2 test to determine the 
association between various HPV16 variants, age and histopathologic status of the cancer patients. 
Fisher’s exact test was employed where small numbers were compared. P-value less than 0.05 has 
been considered as stastically significant. 
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RESULTS 
Out of 90 cervical tumor screened by L1 consensus primers, 65(72.2%) were positive for HPV, 
and further genotyping with type-specific primers revealed 92.3% (n = 60) positivity for HPV 16 and 
7.7% (n = 5) for HPV 18. All sixty patients recruited were exclusively infected with HPV-16 and none 
of them showed presence of HPV type 18. The patients belonged to age group 30-80 year with a mean 
age of 51.3 year (SD = 12.8). The patients were divided into two age groups; 30 to 50 years and above 
50 years. All the cases were of squamous cell carcinoma; 23 (38.3%) well-differentiated (WDSCC), 35 
(58.3%) moderately differentiated (MDSCC) and 2 (3.4%) were poorly differentiated squamous cell 
carcinomas (PDSCC). The E6, E7, L1 and the LCR were analyzed for nucleotide variations which 
were compared with the prototype sequence 16 R of the European lineage (E).  
Association between HPV variants and histopathological grades. The E6 variants were 
found to be significantly higher as compared to prototype in both WDSCC (68.2%) and MDSCC 
(69.4%) cases which include only 2 PDSCC cases while prototypes of E7 (86.4%, 86.2% respectively) 
and L1 (60.0%, 73.6% respectively) (Table 1) were most frequent in them. The frequency of LCR 
variants was also found to be more in WDSCC as well as MDSCC (81.8% and 75% respectively) (see 
table 1). 
E6 sequence variations.  Nucleotide sequences of the complete E6 ORF in all 60 cancer 
patients screened were compared with the HPV16 reference sequence. Forty-two (70%) patients 
showed seven different types of E6 gene mutations of which four; G145T, C335T, T350G and T527A 
were missense mutations; Glutamine  Histidine (Q14H), Histidine  Tyrosine (H78Y), Leucine  
Valine (L83V) and Serine  Threonine (S142T) respectively. The remaining three T286A, A289G 
and A532 G led to silent mutations at codon 61, 62 and 143 for amino acids Alanine, Valine and 
Serine respectively .The most frequently observed mutation was the European variant T350G (Fig. 2a) 
which was detected in all 42 (100%) patients either alone (34; 81%) or along with other variants(8; 
19%) (Fig. 1). Additional E6 gene variations were observed only in those cases which showed 350G 
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variation and no case with 350T sequence had any nucleotide change. Majority of cases (85%) were 
found to be of European origin (E), while only 10% to branch NA and 3.3% AA, but none to As, Af1 
or Af2 (Table 3). Interestingly, a novel mutation T527A was recorded along with 350G (Fig.1) for the 
first time.  
 E7 sequence variations. The E7 gene revealed only five nucleotide variations in 8 (13.3%) 
patients whereas rest 52 (86.7%) cases showed prototype sequence. All the variants were silent 
nucleotide alterations of which, one was transversion and four were transition substitution .The silent 
mutation detected were G666A, T732C, T789C, T795G and T828C for amino acids Glutamic Acid 
(E), Phenylalanine (F), Isoleucine (Il), Threonine (T) and Isoleucine (Il) at codons 35, 57, 76, 78 and 
89 respectively. E7 sequencing data indicated 86.7% to branch E (P), 11.6% to Af2, 1.7% to As and 
none to NA, AA, Af1 (Table 3).  
   L1 sequence variations. A partial sequence of L1 gene was screened using 450 bp in 31 
cervical cancer patients. A total of 13 nucleotide variations were detected in 11 (35.5%) patients while 
the majority (20; 64.5%) showed prototype sequence. Of 13 variants, 5 (38.5%) led to missense and 8 
(61.5%) to silent mutations.  
Of four variants found independently (Fig. 1); two were silent mutations, A6667C and A6691G 
coding for Serine. at codon 343 and 351, whereas A6803T and A6964C led to missense mutations, 
Threonine  Serine (T389S) and Lysine  Asparagine (K442N). Most frequently detected L1 
variation A6695C (Fig. 2c) was found in 6 (54.5%) cases. Interestingly, four novel L1 variants 
consisting of 2 silent mutations, at A6667C and A6691G, and 2 missense mutations, Serine  
Phenylalanine (S423F) at C6906T and Glutamine  Proline (Q429P) at A6924C were observed 
(Table 2). The case with novel L1 variants which exhibited silent mutations had only prototype 
sequences at E6, E7 and LCR (Fig. 1).The L1 sequence data showed 67.7% to branch E, 3.2% to 
branch E (G131), 12.9% to AA, 6.5% to NA and none to As, Af1, Af2 while 9.7% were new variants 
(Table 3). 
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 LCR sequence variations. The LCR of HPV-16 showed highest nucleotide variations in 
various known and unknown regulatory binding sites of number of cellular and/or viral 
transcription/regulatory factors. A total of 45 (75%) variant cases that were analyzed showed 17 
different point mutations (9 transitions and 8 transversions). Of these 7(G7521A, A7636C, C7689A, 
T7714G, C7792T, G7826A, A7839C) were detected in the known binding sites for various 
transcription factors such as YY1, AP1, TEF1, NF1 and Oct-1. The most commonly observed LCR 
variation was a transition substitution G7521A (Fig. 2d) detected in 41 (91.1%) patients at one of the 
many YY1 binding sites. This mutation occurred alone in as many as 22 (53.7%) cases (Fig. 1). 
     Another frequently observed LCR variation was a transversion mutation T7714G, detected in 9 
(20%) cases mostly along with G7521A located in the NF1 transcription factor binding site. Two other 
LCR variants T7743G and C7764T were detected upstream to NF1 binding site in 11.1% and 22.2% 
cases respectively. We report here four novel LCR variants, C13T, A7636C, C7678T and G7799A 
(Table 2) of which 3 were transition and 1 (A7636C) was transversion mutations located at the AP1 
binding site. 
      Phylogenetic classification of LCR variants was found to be in the same pattern as observed in E6, 
E7 and L1 showing majority (63.3%) to branch E (P), and only 13.3% to AA, 11.6% to Af1, 3.3% to 
Af2, and none to NA, As. Four (8.3%) novel LCR variants were observed for the first time from India 
(Table 3). 
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DISCUSSION 
HPV variants data is important in developing HPV diagnostics, vaccines and other therapeutic 
approaches to control the virus-induced diseases. HPV 16 variants have been shown to have different 
biological as well as biochemical effects resulting in altered oncogenic potential (1, 47, 59 ). 
Oncogenicity of distinct HPV variants may also differ between geographical regions because of 
difference in  population related distribution of HLA alleles (28).  
  Nucleotide sequence variations observed in E6, E7, L1 genes and LCR of HPV type 16 in 60 
cervical carcinoma cases showed a high prevalence of 350G E6 variants as compared to prototype 
350T in all different histopatholgic grades (WDSCC, MDSCC/ PDSCC). This is in good agreement 
with the previous reports (1, 59) which demonstrated an increased frequency of 350G E6 variants in 
cervical cancer leading to an amino acid change of Leucine to Valine at position 83 (L83V) and this 
has been associated with progression of cervical lesions (59).In contrast , several authors failed to find 
significant role of E6 variants in cervical cancer (19, 33, 50). The prevalence of E6 gene mutation 
studied in a subset of south Indian cervical cancer patients, showed only 20% of cancer patients with 
350G variants which is in sharp contrast to the present study showing 78% of the patients with 350G 
variants.Our results however, are in good agreement with another study by Sathish et al. (36) from 
south-eastern part of India.  
We have observed nucleotide positions 83-144, 146-285 and 351-526 as the most conserved 
regions of HPV 16 E6 which seems to be important for silencing E6 expression using siRNA and/or 
ribozyme treatment. Also, the amino acids located in these regions may play an important 
immunogenic role for new vaccine strategies (21). The amino acid substitution analyzed in this study 
are Q14H, H78Y, L83V which are also observed by Stoppler and his group (47). Most interestingly, a 
hundred percent distribution (100%, 42/42) of HPV 16 E6 European variant 350G was detected either 
alone (81%, 34/42) or in combination with additional E6 gene mutations. The E6 variations, G145T 
and C335T detected with 350G have also been observed in AA, NA, Af1 and Af2 lineages. A novel E6 
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gene mutation T527A (S142T) that replaced serine by threonine was observed in only one (2.4%) case. 
In sharp contrast to reports from China which showed high prevalence of HPV 16 Asian lineage (55) 
,our
 
results as well as the reports of other authors from India (36, 39) suggest complete absence of 
Asian lineage in India. 
HPV 16 E7 gene mutation has been reported to be rare in various geographic and ethnic 
populations world over (16 36). Yet several studies particularly from Japan, Korea and Indonesia have 
reported a high frequency of E7 gene mutation (65-75%) in cervical cancer patients (9, 45). 
Interestingly, a recent report from China showed, 100% of cervical cancer cases having nucleotide 
variation in the HPV16 E7 region (55). In contrast, we observed a highly conserved E7 and as high as 
86.7% patients showed no sequence variation and only 13.3% showed variation in the form of silent 
mutation thus leaving no effect on proteins. Because of conserved E7, it can be far easier target to 
silence its effects at RNA or protein level. Most frequently reported E7 variation A647G has also been 
found to be completely absent in India. Any change in the two transforming genes E6 and E7 may lead 
to altered biological function and oncogenicity of the proteins encoded, which can affect the natural 
history of HPV infection (13).  
The L1 gene also did not reveal any significant variation and 64.5% (20/31) of the samples 
showed prototype sequence. Very few reports are available on the HPV 16 L1 variants (9, 53, 54, 56) 
and none from south Asia. Interestingly, the common L1 variant T6862C observed in all previous 
studies was not detected instead,4 novel nucleotide variations, two silent and two missense mutations 
at codon 343, 351, 423 and 429 were detected (Table 2).This is indicative of hypervariability of L1 
gene in this region. Importance of most frequently observed L1 gene variation A6695 (T353P) lies in 
the fact that a polar uncharged amino acid threonine is replaced by non-polar aliphatic amino acid that 
may have effect on structure or function of L1 protein, which may play an important role in immune 
recognition and vaccine development strategies. Amino acid changes among molecular variants have 
also been shown to affect the efficiency of HPV 16 L1 proteins to self assemble into VLPs (25, 49). 
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This variability could lead to conformational changes within epitopes relevant for viral neutralization 
(44).  
The LCR which contains the upstream regulatory region is the binding sites of various cellular 
and viral transcription factors that either activate or suppress the p97 promoter activity which regulates 
the transcription of various HPV 16 genes, especially the E6 and E7 oncogenes. It has been reported to 
be most variable segment of the HPV 16 genome in different populations (23, 26, 53, 56). We also 
observed similar pattern as 75% (45/60) patients revealed presence of 17 different LCR variants  of 
which 4 (C13T, A7636C, C7678T and G7799A) were found to be novel types, including, a A7636C 
substitution was detected in AP1 binding site (4.4%). Since LCR is the major site for transcriptional 
control of the virus; studies are underway to correlate the observed alterations with the 
biological/biochemical properties with different clinicopathological features of the disease. The 
number of nucleotide alterations was highest in LCR, followed by L1, E6 and E7 gene, and this is in 
good agreement with the previous report (56).The most frequently observed mutation in the LCR was 
G7521A located at the YY1-binding site of as high as 91% cases that causes repression of HPV 
transcription. This mutation has been found to be uniformly distributed in majority of cervical cancer 
patients throughout the world (26, 41, 53, 56) but not in asymptomatic carriers (41). Mutations in the 
YY1 binding sites have been shown to promote the P97 promoter activity by 3 to 6 folds (12, 29). It 
has also been shown to quench AP1 activity thereby repressing HPV 16 transcription (35). The role of 
mutation at YY1 binding site in cancer cases assumes a greater importance as this mutation is absent in 
non-cancerous lesions and asymptomatic carriers (42). Presence of mutation in the binding sites of 
various transcription factors or to their close vicinity is intriguing since these factors enhance the 
transcription activity of HPV 16 oncogenes. A low frequency (4.4%) of mutation found in Oct-1 
binding site appears to be important since oct-1 is an important part of basal transcriptional machinery 
and is known to down-regulate HPV expression (43).  
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 Most interestingly, when the distribution of HPV16 variant with respect to E6, E7, L1 and 
LCR was compared with that of different lineages, an extremely high prevalence of European lineage 
(85%, 86.7%, 67.7% and 63.3% respectively) and complete absence of Asian lineage (36, 39) were 
observed. The occurrence of AA and NA classes in this study is in accordance with other studies 
reported from Southern part of India (56). It is important that HPV variants are correlated with the 
severity of lesions through follow-up data to elucidate the biological significance of HPV 16 variants 
during cervical carcinogenesis thus delineating its utility in developing reliable diagnostics and 
effective therapeutics including vaccines against HPV. 
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Scx17 - - - - G - -  - - - - -  - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - 
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Scx24 - - - - G - -  - - - - -  - A - - - - - - - - - T - - - - -  - - - - - - - - - - - - - 
Scx25 - - - -  - - -  - - - - -  - A - - - - G - - - - - - - - - -  - - - - T - - - - - - - - 
Scx26 - - - -  - - -  - - - - -  T A - - - - G - - - - - - - - - -  C - - - - - - - - - - - - 
Scx27 - - - -  - - -  - - - - -  - - - - - - - - - - - - - - - - -  - G - - - - - - - - - - - 
Scx28 - - - -  - - -  - - - - -  - - - - - - - - - - - - - - - - -  - - - - T - - - - - - - - 
Scx29 - - - -  - - -  - - - - -  - A C - - - - - - - - - A - - - -  C - C - - - - - - - - - - 
Scx30 - - - -  - - -  - - - - -  - A - - - A - C G T T - - - - - G  - - - - - - - - - - - - - 
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Bcx33 - - - -  - - -  A - - - -  - A - - - - - - - - - - - - - - -               
Bcx34 - - - -  - - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx35 - - - -  -  - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx36 - - - -  - - -  - - - - -  - - - - - - - - - - - - - - - - -               
Bcx37 - - - -  - - -  - - - - -  - A - - - - G - - - - - - - - - -               
Bcx38 - - - - G - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx39 - - - - G - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx40 - - - - G - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx41 - - - -  - - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx42 - - - - G - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx43 - - - -  - - -  - - - - -  - A - - - - G - - - - - - - - - -               
Bcx44 - - - - G - -  - - - - -  T A - - - - - - - - - - - - - - -               
Bcx45 - - - -  - - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx46 - - - - G - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx47 T A G T G - G  - C C G -  - A - T - A - C G T T - - - - - G               
Bcx48 - - - - G A -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx49 - - - - G - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx50 T A G T G - -  - - C - -  - A - T - A - C - T T - - A T - -               
Bcx51 - - - - G - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx52 - - - -  - - -  - - - - -  - A - - - - G - - - - - - - - - -               
Bcx53 - - - - G - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx54 - - - - G - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx55 - - - - G - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx56 - - - -  - - -  - - - - -  - A - - - - G - - - - - - - - - -               
Bcx57 - - - - G - -  - - - - -  - A - - - - G - - - - - - - - - -               
Bcx58 - - - - G - -  - - - - -  - A - - T A - C G T T - - - - - G               
Bcx59 - - - - G - -  - - - - -  - A - - - - - - - - - - - - - - -               
Bcx60 - - - -  - - -  - - - - -  - A - - - - - - - - - - - - - - -                
 
 
 
 
FIG. 1. Nucleotide sequence variations among the HPV16 isolates. E6, E7, LCR and L1 
nucleotide positions at which variations were observed are written vertically across the top. 
The identification codes of the samples are indicated along the left. The HPV 16 reference 
DNA sequence is indicated as REF. For each variant sequence, positions that do not vary 
relative to the HPV reference sequences are marked with dashes. 
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FIG.2 (a-d) Sequencing Electropherogram showing frequently detected nucleotide 
variations in different genomic segments of HPV-16.  (a)  E6 T350G, (b) E7 T789C (c) 
L1 A6695C and (d) LCR G7521A Upper panel shows prototype sequence while lower 
panel shows variant sequence indicated by arrow. 
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                                                             TABLE 1. Association of histo-pathological diagnosis with variants 
of E6, E7, LCR AND L1 
 
Gene WDSCC 
N = 22 
MDSCC
b
           
N = 38 
    p-Value 
 Prototype      Variant Prototype Variant
 
E6 
 
7 (31.8 %) 
 
15 (68.2 %) 
 
13 (34.2 %) 
 
25 (69.4%) 
 
0.84 
 
E7 19 (86.4 %) 3 (13.6 %) 33 (86.6 %) 5 (13.8 %) 0.95  
LCR 4 (18.2 %) 18 (81.8 %) 11(28.9 %) 27 (75.0%) 0.35  
L1
a 6 (60.0 %) 4 (40.0 %) 14 (73.6 %) 7 (36.8%) 0.71  
                                          
                                                         a Variant analysis for L1 was done only in 31cases (N=10 in WDSCC, 
                                                            N=19 in MDSCC and N=2 in PDSCC) 
                                                           
b 
Two cases of PDSCC with only prototype were clubbed with MDSCC  
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                       TABLE 2: Novel variants of HPV16 E6, L1 and LCR according to nucleotide position, variant, altered amino 
                                                                                acid and mutation  
 
    Nucleotide 
Position 
Prototype Variant Original amino acid Altered amino acid Codon No. Mutation
 a
No&% of Mutation
 
E6 
 
527 
 
T 
 
A 
 
Serine 
 
Threonine 
 
142 
 
MTs 
 
1 (2.4%) 
 
6667 
 
 
A 
 
C 
 
Serine 
 
Serine 
 
343 
 
STv 
 
2 (18.2%) 
6691 
 
A.       
       
       
       
       
       
       
G Serine Serine 351 STs 1 (9.1%)
6906 
 
C T Serine Phenylalanine 423 MTs 2 (18.2%)
 
L1 
 
 
 
6924 
 
A C Glutamine Proline 429 MTv 1 (9.1%)
 
13 
 
C T - - - Ts 2 (4.4%)
7636 
 
A C - - - Tv 2 (4.4%)
7678 
 
C T - - - Ts 1 (2%)
LCR 
 
 
 
 
7799 
 
G A - - - Ts 2 (4.4%)
 
               
a
 Type of mutation (M=missense, S=silent, Ts=transition, Tv=transversion) 
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                                                              TABLE 3: Frequency distribution of HPV TYPE 16 variants  
                                                                     in different phylogenetic lineages 
 
LINEAGE E6 
N= 60 
E7 
N=60 
L1 
N= 31 
LCR 
N= 60 
European E-(P) - 52 (86.7 %) 21 (67.7 %) 38 (63.3%) 
E - P (350T)   18 (30%) - - - 
E - P (350G)   33 (55%) - - - 
E - G (131) -    
    
    
- 1 (3.2%) -
Asian-American (AA) 2 (3.3%) - 4 (12.9%) 8 (13.3 %) 
North-American (NA) 6 (10%) - 2 (6.5%) - 
African-1 (Af-1) - - - 7 (11.6%)
African-2 (Af-2) - 7 (11.6%) - 2 (3.3%) 
Asian (As) - 1 (1.7%) - -
New variants 1 (1.7%) - 3 (9.7%) 5 (8.3%) 
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